WQQ-345 is a BCAT1 inhibitor with an IC50 value of 10.8 mM. WQQ-345 can lead to a decrease in alpha-KG levels, an upregulation of H3K27me3 expression, a reduction in the expression of glycolytic enzymes (PFKP and LDHA), and impaired glycolytic activity in 67R cells. WQQ-345 shows tumor-suppressing activity in a 67R subcutaneous xenograft model[1].
